GSK Says FDA Rejected Zofran Label Change
GlaxoSmithKline on Monday told a Massachusetts federal judge overseeing multidistrict litigation over its anti-nausea medicine Zofran that the U.S. Food and Drug Administration has rejected a proposed label change that would...To view the full article, register now.
Already a subscriber? Click here to view full article